INTRODUCTION
============

Cancer is a major cause of mortality in both developing and developed countries, with an estimated 14.1 million new cancer cases and 8 million cancer deaths in 2012 \[[@B1]\]. Nevertheless, early detection and advancements in medical treatment have greatly increased the number of cancer survivors. However, many cancer patients experience malnutrition and significant weight loss due to decreased food intake, emotional stress, and tumor-associated metabolic alterations. The nutritional status of cancer patients is a critical determinant of successful treatment and quality of life (QOL). Cancer therapy-induced adverse events also contribute to malnutrition and delays in cancer therapies and may contribute to cancer deaths in a large proportion of patients \[[@B2][@B3][@B4][@B5]\].

Cancer cachexia occurs in up to 80% of patients \[[@B6]\] and is responsible for 20% of cancer-related deaths \[[@B7][@B8]\]. A diagnosis of cancer cachexia is made only if at least three of the following 5 criteria are met: decreased muscle strength, fatigue, anorexia, low fat-free mass index, and abnormal biochemistry findings (increased C-reactive protein \[CRP\] concentration, anemia, and low serum albumin levels), including \> 5% weight loss in less than 12 months \[[@B9][@B10]\]. Tumor-associated development of cancer cachexia is indicated by anorexia and substantial metabolic alteration with respect to carbohydrate, fat, and protein, which increases the risk of severe malnutrition accompanied by the loss of total body mass \[[@B11][@B12]\]. Major alterations in carbohydrate metabolism include increased gluconeogenesis using amino acids and lactic acid, and insulin resistance \[[@B13]\]. Increased gluconeogenesis accompanies peripheral insulin resistance, resulting in the decreased use of glucose in the muscles and muscle wastage \[[@B14]\]. Recent studies have reported cancer cachexia to be associated with the transformation of white adipose tissue to beige adipocytes through the browning, which upregulates the expression of uncoupling protein 1 (UCP-1), accelerating thermogenesis and energy expenditure \[[@B15][@B16]\]. Cachexic patients also experience a significant loss of lean body mass due to increased proteolysis and decreased protein synthesis. Blood amino acid concentrations are often decreased, mostly due to accelerated hepatic gluconeogenesis \[[@B17]\].

Cancer therapies, including surgery, chemotherapy, and radiation, are also associated with malnutrition. Surgery-related adverse effects are mostly derived from the surgical removal of cancerous tissue \[[@B13]\]. The most frequent adverse events include difficulties in chewing and swallowing in oral cancer patients; a previous study reported that approximately 50% of oral cancer patients experienced difficulties in ingestion after surgery \[[@B18]\]. Esophageal resection often induces dysphagia, dumping syndrome, and increased defecation. In fact, 80%--90% and 50%--60% of surgical patients exhibit early satiety and reflux, respectively, after food intake \[[@B19]\]. Also, nutrient absorption is decreased due to decreased hormonal and enzymatic activity owing to removal of pancreas \[[@B13][@B20]\].

Anti-cancer drugs often result in vomiting, mucositis, diarrhea, and dysphagia \[[@B21]\]. Within 24 hours of anti-cancer drug administration, more than 90% of patients complain of nausea and often experience vomiting \[[@B22]\]. Many anti-cancer drugs target not only cancer cells but also other rapidly proliferating normal cells, resulting in adverse events. Many cancer patients undergoing therapy also experience oral mucositis, resulting in difficulties in chewing and swallowing. In cases of gastrointestinal cancers, intestinal mucositis reduces nutrient absorption, leading to malnutrition \[[@B2]\]. Adverse events in radiation therapy are similar to those in chemotherapy, with more than 90% of patients experiencing vomiting \[[@B23]\].

Nutritional support for cancer patients has been achieved by providing high-energy and high-protein nutritional formulas. In recent years, specialized nutritional formulas for cancer patients have been introduced to boost immune regulatory functions and delay muscle degradation. Although the efficacy of oral nutritional interventions remains controversial due to limited evidence, the use of these products to support malnourished cancer patients has grown steadily.

This review has systemically examined the effect of oral nutritional interventions on nutritional and clinical outcomes in cancer patients. We especially focused on outcomes such as nutritional status indices, immune-associated biochemical markers, and QOL assessments to provide insights on their applicability to different outcomes.

MATERIALS AND METHODS
=====================

Database search
---------------

Research articles describing randomized controlled oral nutritional supplements (ONS) and enteral nutrition (EN) intervention trials to assess their efficacy on nutritional outcomes in cancer patients were retrieved from the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Elsevier database of abstracts and citations (SCOPUS) electronic databases. The search terms included cancer, nutritional intervention, EN, ONS, and randomized controlled trials. Studies published in English between November 2001 and May 2015 were included. Parenteral nutrition intervention studies were excluded.

Study selection
---------------

Randomized controlled intervention trials performed in adult oncology patients (\> 19 years of age) were selected. The types of treatment (surgery, chemotherapy, radiotherapy or combinations of therapies) and stages or sites of cancer were not considered criteria for study selection. Control groups received usual diet, routine care or placebo ONS. In this review, ONS was defined as a nutritional formula either in liquid or powder form that was used as a supplement. Papers were excluded if they did not describe an original study ([Figure 1](#F1){ref-type="fig"}).

![Flowchart of the article-selection process.\
Search strategy and number of trials identified for inclusion in the literature review. The searches were performed between November 2001 and May 2015. The search strategy evolved in line with the changes in information technology and was designed with advice from information specialists. The databases searched in the study included Medical Literature Analysis and Retrieval System Online (MEDLINE), and the Elsevier database of abstracts and citations (SCOPUS).](cnr-5-219-g001){#F1}

RESULTS
=======

Study characteristics
---------------------

A total of 28 studies meeting selection criteria were retrieved. The studies included patients with gastrointestinal cancers and cancer of the lung, head and neck, and liver. Ten studies used ONS with isocaloric or isosource formulas, 11 studies compared ONS with standard formulas, and 7 studies compared ONS with usual diets.

The number of papers by cancer site were: 9 for head and neck, 4 for esophageal, 2 for both head and neck and esophageal, 2 for gastric, 2 for liver, 1 for colon, 1 for gastrointestinal, 2 for both pancreatic and gastric, 1 for both reproductive system and lower intestinal tract, and 2 for lung cancer. Two studies did not specify the cancer sites. A large proportion of studies included patients with gastrointestinal cancers, which indicated that these patients were at a high risk for malnutrition. The types of treatment included surgery (15 studies), chemotherapy (1 study), radiotherapy (5 studies), combined therapies (4 studies), and radiofrequency ablation (1 study). Two studies did not mention the treatment regimen.

Nutritional formulas
--------------------

All of the ONS used in the selected studies were nutritionally complete supplements. The supplementation routes included oral (12 studies), enteral (14 studies), and both oral and enteral (2 studies). The ONS were either powdered or liquid, and 1 study used ONS in a jelly form. Twenty-two papers described the name of the product and manufacturer: Forticare from Nutricia (2 studies), Nutrison medium-chain triglycerides (MCT) from Nutricia (1 study), Prosure from Abott (4 studies), Impact from Novartis Consumer Health (5 studies), Reconvan from Fresenius Kabi (2 studies), Supportan from Fresenius Kabi (10 studies), Impact from Nestle Healthcare Nutrition (1 study), Impact from Anjimoto (1 study), Aminoleban EN from Otsuka (2 studies), Neomune from Thai Otsuka Pharmaceutical Company (1 study), E028 Extra from SHS International (1 study), and Nutri-jelly from Dental Innovation (1 study). The daily caloric intake from the products varied between 400 and 640 kcal. Most studies, except for three, used nutritional formulas containing functional compounds. Twenty-five studies used ONS or EN products fortified with functional compounds specifically aimed at boosting immune function and preventing tissue loss. The most frequently used compounds were omega-3 fatty acids (n-3 fatty acids, 17 studies) with or without arginine, ribonucleic acid, and glutamine. Arginine was used in 13 studies with or without fiber, n-3 fatty acids, ribonucleic acids, and glutamine.

Outcomes
--------

The intervention outcomes used in selected studies included indices of nutritional status, inflammation, immune responses, and others. The nutritional status indices included anthropometric measures, biochemical measures, dietary assessments, and combinations of two or more indices. The most frequently used indices were serum albumin level, body weight, serum prealbumin level, serum complete blood cell count (CBC), body mass index (BMI), body composition, serum transferrin level, and patient-generated subjective global assessments (PG-SGA) ([Table 1](#T1){ref-type="table"}). More than half of the studies used serum albumin levels as a measure of nutritional status. Body weight and serum prealbumin levels were used in 16 and 10 studies, respectively.

###### Characteristics and information of the selected studies
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  Ref.         Participants   Control group                                          EN/ONS        Outcome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------ -------------- ------------------------------------------------------ ------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  \[[@B24]\]   64             Esophageal                                             Isocaloric    Leucine, emulsified fish oil                                               **Body weight**, CBC, BMI, **ECOG**, prealbumin, albumin                                              **PGE~2~**, PBMC (cytokine, PGE~2~), ConA-stimulated T-lymphocyte proliferation, cytokine, WBC count                                    Liver & kidney function, PT activity, QOL (EORTC QLQ-C30, OES18, EuroQOL-5D)                                                                                                                                                              4 weeks
  \[[@B34]\]   109            Gastric                                                Standard EN   Arginine, n-3 PUFA, RNA, glutamin                                          Protein, albumin, transferrin                                                                         **SIRS**, **postoperative complication**, **late postoperative period-infectious complication**, **WBC count**                          Motality, **hospital stay**                                                                                                                                                                                                               7 days
  \[[@B79]\]   96             Liver                                                  Usual diet    BCAA                                                                       Body weight, **AMC**, **albumin**, **total cholesterol**, **cholinesterase**                          \-                                                                                                                                      **QOL (SF-36)**                                                                                                                                                                                                                           2 weeks
  \[[@B80]\]   8              Head & neck                                            Isosource     Arginine, n-3 PUFA, nucleotides                                            Pre-illness weight, total body protein, plasma PC fatty acid                                          TNF-α, IL-6, IL-10, CRP, Ig A, G, M general infections, flap anastomosis complications                                                  Hospital stay                                                                                                                                                                                                                             5 days
  \[[@B30]\]   71             Esophageal                                             Standard EN   Arginine, n-3 PUFA, glutamine                                              Body weight                                                                                           IL-6, IL-10, **TNF-α**, IFN, **CRP**, CD3, CD4, CD8, WBC, PMN, lymphocyte count, AE                                                     \-                                                                                                                                                                                                                                        28 days
  \[[@B81]\]   40             Head & neck                                            Standard EN   Arginine, n-3 PUFA, RNA                                                    Albumin, prealbumin, fibrinogen                                                                       CRP, Il-6, TNF, **postoperate complicantion**                                                                                           \-                                                                                                                                                                                                                                        Median 12 days
  \[[@B25]\]   66             Head & neck                                            Usual diet    \-                                                                         Presence of symptoms influencing nutritional status, PG-SGA, **weight loss**                          **Treatment tolerance**                                                                                                                 \-                                                                                                                                                                                                                                        Median 100 days
  \[[@B27]\]   37             Head & neck esophageal                                 Isocaloric    Arginine, n-3 PUFA, RNA                                                    BMI, weight loss, **FM**, CBC, mGPS, NRI, albumin, **plasma antioxidant capacity**, AMS, **WHO PS**   CRP, RCT toxicity                                                                                                                       **Karnofsky index**, QOL (EORTC QLQ-C30, QOL H & N 35)                                                                                                                                                                                    For 5 days before to the end of the RCT (5--7 weeks)
  \[[@B82]\]   50             Gynaecological, urological or lower gastrointestinal   Usual diet    MCT                                                                        Body weight, BMI, dietary assessment                                                                  Feacal calprotectin, gastrointestinal toxicity (IBDQ, IBDQ-B, **VIQ**, RTOG)                                                            \-                                                                                                                                                                                                                                        3 weeks
  \[[@B26]\]   13             Colorectal                                             Usual diet    EPA                                                                        **Body weight**, SGA, dietary assessment, protein, total cholesterol                                  Chemotherapy tolerability                                                                                                               **QOL (EORTC QLQ-C30)**                                                                                                                                                                                                                   12 weeks
  \[[@B38]\]   80             Head & neck                                            Usual diet    \-                                                                         BMI                                                                                                   \-                                                                                                                                      **Percentage of tube feeding use, QOL (EORTC QOL H & N 35)**                                                                                                                                                                              5--7 weeks
  \[[@B83]\]   38             Non specific                                           Isocaloric    High in protein, leucine, emulsified fish oil, specific oligosaccharides   CBC, pre-albumin, albumin, calcium, weight                                                            IL-8, IL-1β, IL-6, TNF-α, IFN-γ, IL-10, CRP, **PGE~2~**, the ex vivo LPS-stimulated cytokine, PGE~2~                                    Liver & kidney function, thromboplastin time, **percentages of EPA and DHA, arachidonic acid of total phospholipid fatty acids of WBC**, **percentages of EPA and DHA**, arachidonic acid, DPA of total phospholipid fatty acids of RBC   7 days
  \[[@B28]\]   40             Lung                                                   Isocaloric    n-3 PUFA                                                                   Handgrip strength, PAM, **Karnofsky performance status**                                              \-                                                                                                                                      **QOL (EORTC QLQ-C30)**                                                                                                                                                                                                                   5 weeks
  \[[@B37]\]   229            Gastrointestinal                                       Isocaloric    MCT                                                                        **Prealbumin**, albumin, **TG**, cholesterol                                                          Gastrointestinal problems, postoperative                                                                                                **Hospital stay**                                                                                                                                                                                                                         At least 5 days
  \[[@B36]\]   32             Head & neck                                            Standard EN   Arginine                                                                   \-                                                                                                    \-                                                                                                                                      Survival, second primary tumor, **locoregional recurrence**                                                                                                                                                                               10 days
  \[[@B84]\]   49             Hepatocellular carcinoma                               Usual diet    BCAA                                                                       **Albumin**, CBC, calorie intake                                                                      Six events (death, recurrence of HCC, rupture of esophageal varices, and liver failure), tumor markers in blood (AFP, L3-AFP)           Envent free survivla rate, **QOL (SF-8)**, liver & kidney function, prothrombin time, **raspiratory rate (npRQ)**, **non-protein respiratory quotient**                                                                                   12 months
  \[[@B85]\]   15             Head & neck                                            Standard EN   Arginine, RNA, n-3 PUFA, glutamine                                         PG-SGA, CBC, albumin, prealbumin, body weight                                                         CRP, WBC, total lymphocyte count, **T-lymphocyte subsets**, ASEPSIS tool, DTH skin test                                                 \-                                                                                                                                                                                                                                        7 days
  \[[@B31]\]   29             Esophageal                                             Standard EN   Arginine, n-3 PUFA, RNA, MCT                                               CBC, platelet count, plasma nitrate nitrite                                                           IL-6, **IL-8**, maximum body temperature, PHA-induced lymphocyte transformation tests, **T-cell subsets**                               **PT activity**, **thrombin-antithrombin 3 complex**, **PIC**, hospital stay                                                                                                                                                              7 days
  \[[@B86]\]   25             Non specific                                           Standard EN   Fish oil, leucine                                                          \-                                                                                                    \-                                                                                                                                      HOMA, **FSR**, **plasma luecine**, **serum glucose**, **insulin**                                                                                                                                                                         1 day
  \[[@B87]\]   40             Non-small cell lung                                    Isocaloric    n-3 PUFA (EPA, DHA)                                                        **REE**, **body weight**, **FFM**, MUAC, **energy intake**, albumin                                   IL-6, CRP, sTNF-p55, HLA-DR expression on monocytes                                                                                     **EPA**, **DHA**, AA in plasma phospholipids                                                                                                                                                                                              5 weeks
  \[[@B88]\]   244            Gastric adenocarcinoma                                 Usual diet    Arginine, n-3 PUFA, RNA                                                    Prognostic nutritional index, albumin, weight loss                                                    Surgical-site infection, infectious complication, complication SIRS, CRP                                                                Hospital stay                                                                                                                                                                                                                             5 days
  \[[@B35]\]   305            Pancreatic & gastric                                   Standard EN   Arginine, n-3 PUFA glutamine                                               CBC, albumin, prealbumin                                                                              **Postoperative complications**, CRP                                                                                                    **Morbidity**, **mortality**, **hospital stay**                                                                                                                                                                                           7 days
  \[[@B32]\]   72             Head & neck                                            Isocaloric    Arginine, fiber                                                            Weight loss, albumin, prealbumin, transferrin                                                         Lyphocytes, postoperative infections complications, **local complications**, gastrointestinal tolerance                                 **Hospital stay**                                                                                                                                                                                                                         Minimum 10 days
  \[[@B33]\]   47             Head & neck                                            Isocaloric    Arginine, fiber                                                            Weight, dietary assesment, albumin, prealbumin, transferrin                                           Postoperative infection complications, **local complecations** gastrointestinal tolerance, lymphocyte                                   **Hospital stay**, mortality                                                                                                                                                                                                              22 ± 12 days
  \[[@B89]\]   36             Head & neck                                            Isocaloric    Arginine, fiber                                                            Albumin, prealbumin, transferrin, body weight                                                         Total No.of lymphocytes, IL-6, TNF-α, CRP                                                                                               \-                                                                                                                                                                                                                                        Average of 20 days
  \[[@B29]\]   111            Head & neck esophageal                                 Standard EN   n-3 PUFA                                                                   Body cell mass, body weight, BMI, **Kondrup score**, **SGA**, handgrip strength, TG                   **IL-6**, TNF-α                                                                                                                         **QOL (EORTC QLQ-C30)**                                                                                                                                                                                                                   14 weeks
  \[[@B90]\]   196            Pancreatic & gastric                                   Standard EN   \-                                                                         Prealbumin, albumin, CBC                                                                              **Postoperative complications**, total lymphocyte count                                                                                 Hospital stay, liver & kidney function                                                                                                                                                                                                    7 days
  \[[@B91]\]   53             Esophageal                                             Standard EN   EPA, DHA                                                                   **Body coposition**, albumin                                                                          IL-10, **IL-8**, TNF-α, postoperative complications, **body temperature**, CRP, IL-6, amyloid A, **serum EPA**, **PBMC membrane EPA**   \-                                                                                                                                                                                                                                        26 days

Bold words indicates those indices with statistical significance.

MUAC, mid-upper arm circumference; REE, resting energy expenditure; FFM, fat free mass; EN, enteral nutrition; ONS, oral nutritional supplements; PGE~2~, prostaglandin E2; PBMC, peripheral blood mononuclear cell; WBC, white blood cell; QOL, quality of life; PC, phosphatidylcholine; PMN, polymorphonuclear; PG-SGA, patient-generated subjective global assessments; SGA, subjective global assessments; LPS, lipopolysaccharide; DPA, docosapentaenoic acid; TG, triglyceride; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; ASEPSIS, Acronym of Seven Wound Assessment of Tool; DTH, delayed-type hypersensitivity; PHA, phytohemagglutinin; HOMA, insulin resistant; FSR, muscle protein fractional synthesis rate; PIC, alpha 2-plasmin inhibitor-plasmin complex; npRQ, raspiratory rate; PAM, physical activity monitor; IBDQ, Inflammatory Bowel Disease Questionnaire; IBDQ-B, Inflammatory Bowel Disease Questionnaire-Bowel sub-set; VIQ, Vaizey Incontinence Questionnaire; RTOG, radiation therapy oncology group; NRI, nutritional risk index; CBC, complete blood cell count; BMI, body mass index; PT activity, prothrombin activity; SIRS, systemic inflammatory response syndrome; AMC, arm muscle circumference; TNF, tumor necrosis factor; IL, interleukin; Ig, immunoglobulin; AE, adverse effect; CRP, C-reactive protein; FM, fat mass; AMS, arm muscular strength; RCT, radiochemotherapy; SF-8, short form-8 health survey; RNA, ribonucleic acid; EPA, eicosapentaenoic acid; BCAA, branched-chain amino acid; MCT, medium-chain triglyceride; DHA, docosahexaenoic acid; n-3 PUFA, n-3 polyunsaturated fatty acid; ECOG, Eastern Cooperative Oncology Group; WHO PS, World Health Organization Performance Status; AA, arachidonic acid.

Plasma CRP level, complications and infection frequencies, serum interleukin-6 (IL-6) levels, white blood cell (WBC) counts, and serum tumor necrosis factor-alpha (TNF-α) levels were the most frequently used indices of inflammation and immune function. A total of 11 studies used plasma CRP and another 11 studies measured the frequencies of complication or infection. Four studies used WBC counts, nine studies used serum IL-6 level, and eight studies used serum TNF-α levels. Patient QOL were assessed in 9 studies by the period of hospital stay, eight studies as QOL score, and 4 studies used either mortality or survival rates.

Efficacy
--------

### 1) *Nutritional status*

Eleven of 28 studies showed that nutritional intervention improved nutritional status indices, especially body weight, performance status scores, and body composition. A four-week intervention in esophageal cancer patients administered ONS containing leucine and fish oil significantly improved body weight change (p \< 0.05) and Eastern Cooperative Oncology Group (ECOG) score (p \< 0.05) \[[@B24]\]. Similarly, nutritional intervention significantly reduced weight loss in head and neck cancer patients (p = 0.024) \[[@B25]\]. Increased body weight gain was observed in colon cancer patients after 12 weeks of nutritional intervention with ONS containing eicosapentaenoic acid (EPA) compared to that of the control patients (4.94 vs. −1.17; p = 0.045) \[[@B26]\]. Head and neck cancer patients in intervention groups showed improved World Health Organization Performance Status (WHO PS) scores (1.00 ± 0.41 vs. 1.67 ± 0.72; p \< 0.05), and fat mass loss (−0.6 ± 0.9 vs. 0.7 ± 1.3 kg; p \< 0.05) \[[@B27]\]. Another study involving lung cancer patients showed that five weeks of nutritional intervention improved Karnofsky performance scores (p = 0.04) \[[@B28]\]. A 14-week intervention trial involving head and neck and esophageal cancer patients improved Kondrup scores only in the experimental group and not in the control group (p \< 0.05) \[[@B29]\].

### 2) *Inflammation and immune function indices*

One or more indices of inflammation and immune function, especially infections, complications, plasma CRP levels, and serum cytokine levels, improved in 65% of the selected studies. Treatment-induced increases in plasma CRP and inflammatory cytokine concentrations were significantly lowered by nutritional intervention \[[@B30]\]. Increases in plasma CRP and TNF-α concentrations in esophageal cancer patients were significantly lowered by four weeks of EN supplementation, which contained arginine, n-3 fatty acid, and glutamine. Patients who received EN containing arginine, n-3 fatty acid, ribonucleic acid, and MCT showed lower serum IL-8 concentration compared to that in the control patients \[[@B31]\]. ONS containing leucine, and fish oil resulted in decreased serum prostaglandin E2 (PGE~2~) concentrations \[[@B24]\].

### 3) *Other measures and indices*

Control group patients had significantly more unplanned hospital admissions during the treatment period compared with the experimental group (p \< 0.05) \[[@B32][@B33]\]. Statistical differences were detected in local complications and fistulas diagnosed by X-ray were less frequent in the experimental group (5.2% experimental group vs. 17.6% control group; p = 0.026). Systemic inflammatory response syndrome (SIRS) disappeared faster and complications were lower in gastric cancer patients who received 1 week of nutrition compared to those in control group patients. The duration of SIRS in the experimental group (1.10 ± 0.89 days) was significantly shorter than that in the control group (2.20 ± 1.02 days; p = 0.036) \[[@B34]\]. Nutrition intervention with EN included arginine, n-3 fatty acid, and glutamine administered for one week decreased infection-associated complications and mortality in pancreatic and gastric cancer patients \[[@B35]\]. Infectious complications were observed in 60 patients (39.2%) in the control group and 43 (28.3%) in the experimental group (p = 0.04). Differences were also observed in overall morbidity (47.1% vs. 33.5%; p = 0.01) and mortality (5.9% vs. 1.3%, p = 0.03)

Twelve of the 28 studies showed significant improvement in other indices, including QOL, survival, and length of hospital stay. In a 10-year follow-up after 10 days of post- or perioperative arginine-containing EN intervention in head and neck cancer patients, the intervention group showed a higher median survival rate (p = 0.019) \[[@B36]\]. In other studies, nutritional intervention reduced the length of hospital stay in head and neck \[[@B32][@B33]\] and gastrointestinal cancer patients \[[@B34][@B35][@B37]\]. The length of postoperative stay was 24.3 ± 14.0 days in the experimental group (EN with arginine and fiber) compared to 36.1 ± 27.0 days in the control group (p = 0.036) \[[@B32]\].

QOL measurements in head and neck cancer patients improved in the intervention group compared to those of the control group. Nutritional supplementation also significantly improved social functions of colon cancer patients and physical function, cognitive function, and social function in lung cancer patients \[[@B28]\]. After receiving radiotherapy, the overall health-related QOL score in the experimental group was significantly higher than that of the control group (no intervention) (p \< 0.001) The intervention group (ONS containing leucine and fish oil) showed significantly better global health status (B = 12.2, p = 0.04), physical function (B = 5.3, p = 0.04), cognitive function (B = 20.7, p \< 0.01), and social function (B = 22.1, p = 0.04) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQC30) subscales than the control group (B is the difference between the intervention and control groups) \[[@B28]\].

DISCUSSION
==========

The main objective of this review was to evaluate the efficacy of ONS and EN in malnourished cancer patients based on a systematic review of recent randomized, controlled nutrition intervention trials. Despite substantial research efforts on cancer treatment, advancements in nutritional support to improve patient QOL and increase treatment efficacy are limited. In this study, we found that ONS- or EN-based nutritional intervention can significantly improve indices of nutrition status, immune functions, and QOL despite a large variability in outcome measures. Additionally, cancer treatment-associated increases in inflammatory response could be alleviated through better nutritional management. Due to the complicated nature of the disease and frequent adverse events due to treatment, nutritional intervention studies in cancer patients have been extremely difficult, especially with high dropout rates. Substantial variabilities in biomarkers caused by site specificity, different treatment protocols, and disease stages also affect the intervention results.

We found that the indices used to measure the efficacy of nutritional interventions have been expanded in recent studies compared to those in previous years. The classic indices of nutritional status in malnourished patients include body weight and serum albumin levels. We found that 48.3% and 58.6% of the collected studies assessed body weight and serum albumin levels, respectively. Among those, only 28.6% and 11.8% of the studies reported improvements. Albumin has a relatively long half-life (14 to 20 days) and has been used to reflect chronic nutritional status \[[@B39]\]. Although albumin has been associated with death rate and duration of hospitalization \[[@B40]\], non-nutritional factors including iron deficiency, estrogen, chronic blood loss, and age affect circulating concentrations of albumin \[[@B41]\] indicating albumin alone might not be an accurate marker of nutritional status \[[@B42]\].

Body weight in combination with albumin and other blood markers has been widely used to assess the nutritional status of cancer patients. It has been suggested that body weight is a key measure to assess not only malnutrition but also the risk of adverse events associated with cancer treatments. In recent clinical practice, serum triglyceride (TG) and cholesterol levels are used as markers of cachexia \[[@B44]\]. Cholesterol has been proposed to alleviate tissue inflammatory responses associated with cancer \[[@B45]\], which might be related to the development of cachexia leading to malnutrition.

Although PG-SGA and nutritional risk index (NRI) are ideal assessment methods to evaluate nutritional status, they were not commonly used in the studies included in this review. PG-SGA is a standard nutritional assessment tool recommended by the Oncology Nutrition Dietetic Practice Group of the American Dietetic Association and Oncology Nursing Society \[[@B46]\]. Although PG-SGA scores are determined based on changes in body weight, dietary intake, and physical symptoms, the assessment itself requires highly trained medical staff and well-established guidelines. Therefore, patient PG-SGA scores often differ when measured by different medical staff; in addition, not enough personnel are available in clinical settings \[[@B47]\]. Other nutritional assessment tools include the Malnutrition Universal Screening Tool (MUST), Prognostic Nutritional Index, NRI, Nutritional Screening Tool, Maastricht Index, Instant Nutrition Assessment, and Mini Nutritional Assessment.

The most significant adverse effect of cancer treatment is cytotoxicity in rapidly proliferating normal cells, including epithelial and immune cells, making patients vulnerable to mucositis and infections. Both chemotherapy and radiotherapy accelerate inflammatory responses, which are also related to mucositis and infections. Proinflammatory cytokines and other markers of inflammation are often elevated in patients undergoing cancer therapy. Surgical patients with colon cancer have higher concentrations of IL-6 and IL-10 \[[@B48]\]. Also, patients with prostate cancer who receive radiotherapy have elevated concentrations of IL-6 \[[@B49]\]. The markers of inflammatory responses used in the studies in this review include CRP (11 studies), amyloid A (1 study), TNF-µ (8 studies), IL-6 (9 studies), IL-10 (4 studies), IL-8 (3 studies), interferon-γ (2 studies), IL-1µ (1 study), and PGE~2~ (2 studies). However, most of the studies did not find significant differences in the concentrations of serum inflammatory markers, possibly due to wide concentration variations, indicating the serum markers of inflammation may not accurately reflect the efficacy of nutritional interventions.

The most frequently used indices of immune function the selected studies were WBC counts (4 studies), total lymphocyte counts (6 studies), T-cell subset populations (4 studies) and adverse events including infections and complications (10 studies), treatment toxicity (6 studies), and other adverse effects (2 studies). Among these indices, T-cell subset populations and events reflecting infections and complications responded relatively well to nutritional intervention.

QOL measures are clinically meaningful indices to determine the efficacy of nutritional interventions in cancer patients. Only eight of the 28 studies used QOL questionnaires as an intervention outcome, and 75% showed positive results with nutritional intervention. A meta-analysis on the efficacy of ONS in malnourished cancer patients indicated that nutritional interventions can improve QOL; however, its effects on survival, body weight, and energy intake are inconsistent \[[@B50]\]. With gradually increasing cancer survival rates, QOL is a valuable intervention outcome of many types of cancer, although QOL assessment results have been rarely applied in clinical settings due to large differences in clinical interpretation of QOL. Recently, however, guidelines for interpreting changes in EORTC QLQ-30 scores have been proposed \[[@B51]\], which includes 5 functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), and a global health status/QOL.

As shown in [Table 2](#T2){ref-type="table"}, many ONS and EN products used in intervention trials contain functional compounds to improve reduced immune function and increased inflammatory responses. N-3 fatty acids, either as fish oil or long-chain fatty acids (EPA and docosahexaenoic acid \[DHA\]), were the most frequently used immunonutrient components. The use of fish oil as an alternative lipid source in surgical and critically ill patients has been routinely suggested. Long-chain n-3 fatty acids such as EPA and DHA are easily incorporated into cell membranes, altering the properties, followed by accelerated cellular signal transduction pathways. Additionally, eicosanoids synthesized from n-3 fatty acids exert anti-inflammatory effects, while those from n-6 fatty acids accelerate inflammatory responses. Among ONS provided in these 28 studies, 19 studies (68%) contained n-3 fatty acids or fish oil; 9 studies indicated that the intervention suppressed inflammatory responses. An extensive review of nutrition intervention studies in postsurgical and critically ill patients indicated that the use of fish oil in surgical and critically ill patients has not been proven to be beneficial, possibly due to the limited number of studies \[[@B52]\]. However, the use of fish oil in combination with other functional components such as arginine and antioxidants may improve the nutritional status of postsurgical and critically ill patients, respectively. Recent studies have also indicated that long-chain n-3 fatty acid supplementation may exert detrimental effects in acute infections \[[@B53]\], implying that caution may be required in immunosuppressed patients.

###### Frequency of outcomes analyzed in the selected studies
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  Outcome                        Reference                                                                                                                                                                 
  ------------------------------ ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Nutrition status                                                                                                                                                                                         
                                 Anthropometry                                                                                                Body weight                                                  \[[@B24][@B25][@B26][@B27][@B29][@B30][@B32][@B33][@B79][@B80][@B82][@B83][@B85][@B87][@B88][@B89]\]
  Body composition               \[[@B27][@B29][@B87][@B91]\]                                                                                                                                              
  Arm muscle circumference       \[[@B79][@B87]\]                                                                                                                                                          
  BMI                            \[[@B24][@B27][@B29][@B38][@B82]\]                                                                                                                                        
  Handgrip strength              \[[@B28][@B29]\]                                                                                                                                                          
                                 Biochemical                                                                                                  CBC                                                          \[[@B24][@B27][@B31][@B35][@B83][@B84][@B85][@B90]\]
  Protein                        \[[@B26][@B34][@B80]\]                                                                                                                                                    
  Albumin                        \[[@B24][@B27][@B32][@B33][@B34][@B35][@B37][@B79][@B81][@B83][@B84][@B85][@B87][@B88][@B89][@B90][@B91]\]                                                                
  Prealbumin                     \[[@B24][@B32][@B33][@B35][@B37][@B81][@B83][@B85][@B89][@B90]\]                                                                                                          
  Fibrinogen                     \[[@B81]\]                                                                                                                                                                
  Transferrin                    \[[@B32][@B33][@B34][@B89]\]                                                                                                                                              
  Total cholesterol              \[[@B26][@B37][@B79]\]                                                                                                                                                    
  Triglyceride                   \[[@B29][@B37]\]                                                                                                                                                          
                                 Dietary assessment                                                                                                                                                        \[[@B26][@B33][@B82][@B84][@B87]\]
                                 Assessment tool                                                                                              Kondrup score                                                \[[@B29]\]
  ECOG performance status        \[[@B24]\]                                                                                                                                                                
  Karnofsky performance status   \[[@B28]\]                                                                                                                                                                
  WHO PS                         \[[@B27]\]                                                                                                                                                                
  PG-SGA                         \[[@B25][@B26][@B29][@B85]\]                                                                                                                                              
  NRI                            \[[@B27]\]                                                                                                                                                                
  Inflammation & immune                                                                                                                                                                                    
                                 Biochemical                                                                                                  CRP                                                          \[[@B27][@B30][@B35][@B80][@B81][@B83][@B85][@B87][@B88][@B89][@B91]\]
  Amyloid A                      \[[@B91]\]                                                                                                                                                                
  TNF-alpha                      \[[@B29][@B30][@B80][@B81][@B83][@B87][@B89][@B91]\]                                                                                                                      
  IL-6                           \[[@B29][@B30][@B31][@B80][@B81][@B83][@B87][@B89][@B91]\]                                                                                                                
  IL-10                          \[[@B30][@B80][@B83][@B91]\]                                                                                                                                              
  IL-8                           \[[@B31][@B83][@B91]\]                                                                                                                                                    
  interferon gamma               \[[@B30][@B83]\]                                                                                                                                                          
  IL-1beta                       \[[@B83]\]                                                                                                                                                                
  WBC count                      \[[@B24][@B30][@B34][@B85]\]                                                                                                                                              
  Total lymphocyte count         \[[@B30][@B32][@B33][@B85][@B89][@B90]\]                                                                                                                                  
  T-cell subsets                 \[[@B24][@B30][@B31][@B85]\]                                                                                                                                              
  Feacal calprotection           \[[@B82]\]                                                                                                                                                                
  PGE~2~                         \[[@B24][@B83]\]                                                                                                                                                          
  Immunoglobulin A, G, and M     \[[@B80]\]                                                                                                                                                                
                                 Others                                                                                                       Complication & infection                                     \[[@B32][@B33][@B34][@B35][@B37][@B80][@B81][@B88][@B90][@B91]\]
  Treatment toxicity             \[[@B25][@B26][@B27][@B32][@B33][@B82]\]                                                                                                                                  
  Adverse effect                 \[[@B30][@B84]\]                                                                                                                                                          
  Maximum body temperature       \[[@B31][@B91]\]                                                                                                                                                          
  Others                                                                                                                                                                                                   
                                 QOL                                                                                                                                                                       \[[@B24][@B26][@B27][@B28][@B29][@B38][@B79][@B84]\]
  Motality & survival                                                                                                                         \[[@B33][@B34][@B35][@B36]\]                                 
  Length of hospital stay                                                                                                                     \[[@B31][@B32][@B33][@B34][@B35][@B37][@B80][@B88][@B90]\]   

BMI, body mass index; CBC, complete blood cell count; ECOG, Eastern Cooperative Oncology Group; PG-SGA, patient-generated subjective global assessment; CRP, C-reactive protein; QOL, quality of life; WHO PS, World Health Organization Performance Status; NRI, nutritional risk index; TNF, tumor necrosis factor; IL, interleukin; WBC, white blood cell; PGE~2~, prostaglandin E2.

Cachexia is accelerated by increased concentrations of inflammatory cytokines and is associated with accelerated immune response \[[@B54]\]. In particular, TNF-α, IL-6, IL-1, and interferon-γ have been shown to evoke cancer cachexia \[[@B55]\]. TNF-α, a cachectin, stimulates other secondary cytokines produced in monocytes and macrophages, including IL-1β, IL-6, and IL-8 \[[@B56]\]. TNF- accelerates muscle wasting, anorexia, and fatigue. Increased IL-1β concentration is associated with cachexia progress and anorexia development \[[@B57]\]. IL-6 also produced in cancer cells \[[@B58]\] possibly worsening cachexia. The activated leukocytes are responsible for the production of pro-inflammatory molecules including eicosanoids, inflammatory cytokines, reactive oxygen species, and platelet-activating factors \[[@B59]\]. A previous study showed that DHA- and EPA-rich fish oil supplementation significantly reduced secretion of IL-1β, IL-6, and granulocyte colony-stimulating factor from lipopolysaccharide-stimulated peripheral blood mononuclear cells \[[@B60]\]. A recent mechanistic study showed that dendritic cells exposed to arachidonic acid and DHA reduced T helper cell, which may explain their anti-inflammatory activities \[[@B61]\]. Long chain n-3 polyunsaturated fatty acids (PUFAs) also suppress the nuclear factor kappa-B (NF-κB) signaling pathway, thereby decreasing macrophage production of pro-inflammatory cytokines \[[@B62]\]. In this review, 9 of the 18 studies that used ONS containing fish oil or n-3 fatty acids reported improvements in inflammatory markers.

Arginine was used in 14 studies. It is an important immune regulatory basic amino acid \[[@B63]\] involved in the production of nitric oxide associated with innate immunity \[[@B64]\]. Serum arginine concentration is decreased in cancer patients \[[@B65]\]. Tumor-associated arginine deprivation plays a central role in T-cell-mediated anti-tumor activity \[[@B66]\].

Nucleotides exert immune-stimulatory effects \[[@B67]\]. Preclinical studies have shown that nucleotides, ribonucleotides, and nucleic acids stimulate Th1 and Th2 responses \[[@B68][@B69][@B70]\] Nucleotides also accelerate the production of IL-7 in primary cultured murine intestinal epithelial cells promoting intestinal immune function \[[@B71]\].

Among selected studies, 2 studies involving liver cancer patients used branched-chain amino acid (BCAA) including leucine, isoleucine, and valine. Hepatocyte growth factor (HGF) stimulates the proliferation and functions of hepatocytes, and BCAA induces HGF production in the liver \[[@B71]\]. BCAA supplemental therapy has also been used to prevent progressive liver failure \[[@B72]\].

Glutamine has been shown to exert mucosal preservation and immune-stimulatory effects. Extracellular glutamine stimulates the proliferation of T-lymphocytes \[[@B73]\]. Cancer cells have higher glutaminase activity to convert more glutamine to glutamic acids \[[@B74][@B75]\]. Glutamine supplementation also alleviates cancer treatment-induced mucositis by stimulating rapid epithelial cell production \[[@B76][@B77]\].

These results indicate that several functional components such as n-3 fatty acids, arginine, nucleotides and glutamine may be best used in medical foods for cancer patients despite the variabilities in study settings. Most of the studies used ONS containing more than one functional component and showed improvement in at least one or more markers. Although it is difficult to determine the independent effects of these functional components, commercial products use these compounds to accelerate the efficacy of ONS, which will benefit the patient. Further clinical trials are required to determine the efficacy of individual component although the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on nutrition in cancer patients suggested that nutrition intervention in cancer patients exerts a moderate degree of efficacy.

A major limitation of this review is the small number of intervention studies. In addition, the studies used different groups of cancer patients with different cancer sites and treatment protocols, which may affect the efficacy of nutritional interventions (less than one month), which might not be sufficient to show the effects of the intervention. Additionally, the control groups used in each study were defined differently (7 studies used usual care, 11 studies used standard EN or ONS, and 10 studies used placebo controls), which may have affected the study results.

CONCLUSION
==========

Despite its limitations, the results of this review suggest that nutritional intervention improves the indices of nutritional status, inflammation, immune function, and QOL. Nutritional status indices, QOL measures and duration of hospital stay were improved in about 40% of studies. One or more markers of immune function and inflammatory responses were improved by ONS in 65% of selected studies. Based on the reported mechanistic insights on malnutrition in cancer patients, nutritional formulas containing extra functional components should be considered for further development. Further studies in homogeneous subsets of cancer patients with more specific indices are required to minimize the variation in intervention studies.
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